Prospera Private Wealth LLC Takes $216,000 Position in GSK plc (NYSE:GSK)

Prospera Private Wealth LLC acquired a new position in shares of GSK plc (NYSE:GSK) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,276 shares of the pharmaceutical company’s stock, valued at approximately $216,000.

Several other large investors also recently modified their holdings of the company. 1832 Asset Management L.P. increased its position in shares of GSK by 9.1% during the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after buying an additional 257 shares during the period. Boltwood Capital Management increased its position in shares of GSK by 2.5% during the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares during the period. First Affirmative Financial Network increased its position in shares of GSK by 4.7% during the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after buying an additional 283 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 303 shares during the period. Finally, Mesirow Financial Investment Management Inc. increased its position in shares of GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 323 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Down 0.3 %

Shares of NYSE GSK opened at $33.36 on Thursday. The stock has a market capitalization of $69.14 billion, a P/E ratio of 21.66, a P/E/G ratio of 1.28 and a beta of 0.66. The company has a 50-day moving average price of $38.46 and a 200-day moving average price of $40.49. GSK plc has a 1 year low of $32.83 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 99.35%.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. According to MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.